L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat

Behavioural Pharmacology

Volumn 26, Issue , 2015, Pages 101-108

  Huot, Philippe ^a,b,c   Johnston, Tom H ^a   Koprich, James B ^a   Espinosa, Maria C ^a   Reyes, Maria Gabriela ^a   Fox, Susan H ^a,b   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

6 OHDA lesioned rat; abnormal involuntary movements; dyskinesia; L 745,870; L DOPA; Parkinson's disease; rotarod

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ANTIPARKINSON AGENT; DESIPRAMINE; DOPA; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; PARGYLINE; 3-((4-(4-CHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-1H-PYRROLO(2,3-B)PYRIDINE; LEVODOPA; OXIDOPAMINE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; LEVODOPA-INDUCED DYSKINESIA; LOW DRUG DOSE; MACACA; NONHUMAN; RAT; ROTAROD TEST; SPRAGUE DAWLEY RAT; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG INTERACTION; DYSKINESIA, DRUG-INDUCED; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; SPECIES DIFFERENCE;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; OXIDOPAMINE; PARKINSONIAN DISORDERS; PYRIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 84925519907     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000096     Document Type: Article

References (41)

1. Ariano MA,Wang J, Noblett KL, Larson ER, Sibley DR (1997). Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res 752:26-34.
2. Barnum CJ, Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Tignor S, et al. (2012). Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α-and β-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol Biochem Behav 100:607-615.
3. Beaulieu JM, Gainetdinov RR (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182-217.
4. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN (2005). Combined blockade of AMPA and NMDA glutamate receptors reduces levodopainduced motor complications in animal models of PD. Exp Neurol 196:422-429.
5. Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR (1997). Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci 18:186-188.
6. Carey RJ (1991). Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance. Brain Res 568:205-214.
7. Cenci MA, Lundblad M (2007). Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9:Unit 9.25.
8. DeLong MR (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
9. DeLong MR, Wichmann T (2007). Circuits and circuit disorders of the basal ganglia. Arch Neurol 64:20-24.
10. Duvoisin RC, Heikkila RE, Manzino L (1982). Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway. Neurology 32:1387-1391.
11. Fahn S (2008). The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23 (Suppl 3):S497-S508.
12. Flores G, Liang JJ, Sierra A, Martínez-Fong D, Quirion R, Aceves J, Srivastava LK (1999). Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience 91:549-556.
13. Graveland GA, DiFiglia M (1985). The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum. Brain Res 327:307-311.
14. Hely MA, Morris JG, Reid WG, Trafficante R (2005). Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190-199.
15. Hornykiewicz O, Kish SJ (1987). Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34.
16. Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM (2012). L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 342:576-585.
17. Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM (2010). The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov Disord 25:2084-2093.
18. Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM (2009). New insights into the organization of the basal ganglia. Curr Neurol Neurosci Rep 9:298-304.
19. Kramer MS, Last B, Getson A, Reines SA (1997). The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 54:567-572.
20. Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, et al. (1996). 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem 39:1941-1942.
21. Lévesque M, Wallman MJ, Parent A (2004). Striosomes are enriched in glutamic acid decarboxylase in primates. Neurosci Res 50:29-35.
22. Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, et al. (2012). Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79:163-169.
23. Lundblad M, Vaudano E, Cenci MA (2003). Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPAinduced dyskinesia. J Neurochem 84:1398-1410.
24. Marin C, Rodriguez-Oroz MC, Obeso JA (2006). Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp Neurol 197:269-274.
25. Marsden CD (1982). The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 32:514-539.
26. Mauger C, Sivan B, Brockhaus M, Fuchs S, Civelli O, Monsma F Jr (1998). Development and characterization of antibodies directed against the mouse D4 dopamine receptor. Eur J Neurosci 10:529-537.
27. Miller JA, Zahniser NR (1987). The use of 14C-labeled tissue paste standards for the calibration of 125I-labeled ligands in quantitative autoradiography. Neurosci Lett 81:345-350.
28. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998). Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
29. Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, et al. (2005). 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology 49:112-121.
30. Parent A, Hazrati LN (1995). Functional anatomy of the basal ganglia. I. The corticobasal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 20:91-127.
31. Parent A, Sato F,Wu Y, Gauthier J, Lévesque M, Parent M (2000). Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci 23:S20-S27.
32. Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, et al. (1997). Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther 283:636-647.
33. Paxinos G, Watson C (2007). The rat brain in stereotaxic coordinates. Sydney: Academic Press.
34. Picconi B, Centonze D, Håkansson K, Bernardi G, Greengard P, Fisone G, et al. (2003). Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506.
35. Rivera A, Cuéllar B, Girón FJ, Grandy DK, de la Calle A, Moratalla R (2002). Dopamine D4 receptors are heterogeneously distributed in the striosomes/ matrix compartments of the striatum. J Neurochem 80:219-229.
36. Rozas G, Labandeira García JL (1997). Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res 749:188-199.
37. Rozas G, Guerra MJ, Labandeira-García JL (1997). An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2:75-84.
38. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, et al. (2003). Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18:872-883.
39. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000). CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777-787.
40. Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM (2009). Dopamine D3 receptor stimulation underlies the development of L-DOPAinduced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis 35:184-192.
41. Zhang K, Tarazi FI, Baldessarini RJ (2001). Nigrostriatal dopaminergic denervation enhances dopamine D(4) receptor binding in rat caudate-putamen. Pharmacol Biochem Behav 69:111-116.